Clinical Trials · NCT02270983

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Name: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Linaclotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Forest Laboratories
Enrollment: 254
Start date: Oct 2014
Locations: 77 sites, United States
Primary endpoint: Change From Baseline in 8-Week SBM Frequency Rate (SBMs/Week)

View Linaclotide compound reference